Liraglutide Acetate CAS 204656-20-2 Custom Peptide Synthesis

Basic Info

Model No.: 204656-20-2

Additional Info

Packaging: AS REQUIRED

Productivity: KGS

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: TRUE MANUFACTURER

Certificate: GMP Peptide

Product Description

We have engaged in offering Liraglutide (NN2211) CAS 204656-20-2 for many years. Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1). Liraglutide 204656-20-2 like a panacea that widely used to treat type 2 diabetes and obesity.

Cas No.: 204656-20-2

Synonyms: Liraglutide;Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-;Liraglutida;Liraglutida [inn-spanish];Liraglutide [usan:inn];Liraglutidum;Liraglutidum [inn-latin];N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glp-1-(7-37)-peptide

Molecular Formula: C172H265N43O51

Molecular Weight:

Purity: ≥98%

Packing: Export worthy packing

Material Safety Data Sheet: Available on request

Usage: Liraglutide (CAS 204656-20-2) is one API approved by EU/FDA for the treatment of diabetes,

Liraglutide (CAS 204656-20-2) is a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist). It can be used in the treatment of type 2 diabetes. Liraglutide (CAS 204656-20-2) has been formulated into finished dosage forms and marketed under the trade name of Victoza by Novo Nordisk Pharma.

It has been approved by the European Medicines Agency on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.